Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms
The issuer is solely responsible for the content of this announcement.
The issuer is solely responsible for the content of this announcement.